There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Doctors say it's increasingly common for adults who've never had allergies to suddenly experience symptoms like sneezing, ...